NCT
INICIO RECIENTES ARCHIVO COVID-19
INICIO RECIENTES ARCHIVO PUBLICAR INSTRUCCIONES
PARA AUTORES COVID-19 ENTRAR / REGISTRARSE HISTORIA NOSOTROS DIRECTORIO CONTACTO
Neumonía adquirida en la comunidad. Revisión y actualización con una perspectiva orientada a la calidad de la atención médica

Renata Báez-Saldaña, Carlos Gómez-Zamora, Carlos López-Elizondo, Héctor Molina-Corona, Araceli Santillán-Martínez, Julia Sánchez-Hernández, Jonathan Castillo-Pedroza, María Elena Martínez-Rendón, Salomón Aguilar-Medina, Verónica González-López, Nachelly Orozco-González, Jorge Salas-Hernández, Genoveva Carvajal-Gómez, Cristóbal Guadarrama-Pérez, Rogelio Pérez-Padilla





2013, Suplemento 1

2013; 72 (S1)






RESUMEN

La neumonía adquirida en la comunidad (NAC) es una de las primeras causas de morbilidad y mortalidad en México y en el mundo. La generación del nuevo conocimiento para mejorar la prevención, diagnóstico, tratamiento y pronóstico, se origina de los estudios de investigación clínica; sin embargo, generalmente hay una brecha entre el proceso de atención médica de un paciente con NAC, cuando se compara con las recomendaciones basadas en la mejor evidencia científica disponible. El proceso de mejoramiento de la calidad de la atención médica implica necesariamente incorporar precisamente el nuevo conocimiento científico en el proceso de atención médica. Es de llamar la atención que la NAC es una de las patologías para las que hay medidas definidas de calidad de la atención médica para la certificación de instituciones de salud. El propósito del presente documento es proporcionar los elementos necesarios para sistematizar la atención de pacientes con esta enfermedad, facilitando con ello la toma de decisiones relacionadas al diagnóstico, tratamiento y prevención para finalmente mejorar la calidad de la atención médica de estos pacientes.

PALABRAS CLAVE

Neumonía adquirida en la comunidad, calidad de la atención en neumonía adquirida en la comunidad, indicadores de calidad de la atención en neumonía adquirida en la comunidad.

REFERENCIAS

  1. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of Guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumoniae. Am J Med 2004;117:726-731.

  2. http://www.who.int/mediacentre/factsheets/fs310/en/index.html

  3. Joniken C, Heiskanen L, juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993;137:977-988.

  4. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the Intensive Care Unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Available online: http://ccforum.com/content/10/S2/S1

  5. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294:2712-2719.

  6. http://www.dgepi.salud.gob.mx/anuario/index.html# Dirección General de Epidemiología, Secretaría de Salud, México.

  7. http://sinais.salud.gob.mx/mortalidad/

  8. Metersky ML, Abend SL, Meehan TP. What have we learned about how to measure quality of care for patients with community-acquired pneumonia? Respir Care Clin 2005;11:87-98.

  9. Nathwani D, Rubenstein E, Barlow G, et al. Go guidelines for community acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001;32:728-741.

  10. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patientes with pneumonia. JAMA 1997;278:2080-2084.

  11. Rhew DC, Goetz MB, Shekelle PG. Evaluating quality indicators for patients with community-acquired pneumonia. Jt Comm J Qual Improv 2001;27:575-590.

  12. Mohr JJ, Mahoney CC, Nelson EC, et al. Improving health care, part 3: clinical benchmarking for best patient care. Jt Comm J Qual Improv 1996;22:559-616.

  13. Simpson SH, Marrie TJ, Majumdar SR. Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. Respir Care Clin 2005;11:1-13.

  14. Plan for Introducing Joint Commission Hospital Core Measure Requirements: http://wwwb.jcaho.org/perfmeas/coremeas/implement.html

  15. Ramírez JA: Community-acquired pneumonia. Organization Investigators. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med 2005;26:543-552.

  16. Gómez ZCA, Báez SR. Calidad de la atención médica en pacientes con diagnóstico de neumonía adquirida en la comunidad en un Hospital de Referencia de Enfermedades Respiratorias. Tesis de Especialidad de Neumología, UNAM, INER. 2010.

  17. Ramírez J. Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia. Respir Care Clin N Am 2005;11:35-44.

  18. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51.

  19. Nelson S, Summer WR. Innate immunity, cytokines, and pulmonary host defense. Infect Dis Clin Norht Am 1998;12:555-567.

  20. Delclaux C, Azoulay E. Inflammatory response to infectious pulmonary injury. Eur Respir J 2003;22(Suppl. 42):10s-14s.

  21. Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005;26:11.

  22. Tsai KS, Grayson MH. Pulmonary defense mechanisms against pneumonia and sepsis. Curr Opin Pulm Med 2008;14:260-265.

  23. Happel KI, Bagby GJ, Nelson S. Host defense and bacterial pneumoniae. Semin Respir Crit Care Med 2004;25:43-52.

  24. Welsh DA, Mason CM. Host defense in respiratory infections. Med Clin North Am 2001;85:1329-1347.

  25. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumoniae in adults: A population-based case-control study. Eur Respir J 1999;13:349.

  26. Gray BM, Converse GM, Dillon HC. Epidemiologic studies of Streptocuccus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980;142:923-933.

  27. Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 1986;18(Suppl A):35-45.

  28. Lloyd EN, O’Dempsey TJD, Baldeh I, et al. Nasopharyngeal carriage of pneumococci in Gambian children and their families. Pediatr Infect Dis J 1996;15:866-871.

  29. O’Dempsey TJD, McArdle TF, Morris J, et al. A study of risk factors for pneumococcal disease among children in a rural area of West Africa. Int J Epidemiol 1996;25:885-893.

  30. Busse WW. Pathogenesis and sequelae or respiratory infections. Rev Infect Dis 1991;13(Suppl 6):S477-S485.

  31. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002;51:98-104.

  32. Wunderink RG, Waterer GW. Community-acquired pneumoniae: pathophysiology and host factors with focus on posible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004;18:743.

  33. British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: update 2009. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA, Pneumonia Guidelines Committee of the BTS Standards of Care Committee. Thorax 2009; 64 suppl III s1-s55.

  34. Mandell LA. Spectrum of microbial etiology of community acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials. Clin Infect Dis 2008;47:S189-S192.

  35. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-1180.

  36. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849.

  37. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumoniae. Am J Respir Crit Care Med 2001;163:1730-1754.

  38. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005;41:1438.

  39. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Review Thorax 2012;67:71-79.

  40. Levy M, dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988;93:43-48.

  41. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784.

  42. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumoniae by history and physical examination. JAMA 1997;278:1440.

  43. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Guidelines from The Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumoniae in adults. Clin Infect Dis 2000;31:347-382.

  44. Consenso Nacional de uso de antimicrobianos en la neumonía adquirida en la comunidad. Neumología y Cirugía de Tórax 2004;63:67-78.

  45. Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27:358.

  46. Reynolds JH, Banerjee AK. Imaging pneumonia in immunocompetent and immunocompromised individuals. Curr Opin Pulm Med 2012;18:194-201.

  47. Kantor HG. The many radiologic facies of pneumococal pneumonia. AJR 1981;137:1213-1220.

  48. Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001;18:196-208.

  49. Tarver RD, Teague SD, Heitkamp DE, Conces DJ Jr. Radiology of community-acquired pneumonia. Radiol Clin North Am 2005;43:497-512.

  50. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Jansen HM, Boersma WG. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241-249.

  51. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumoniae: limited yield, minimal impact on treatment decisions. Chest 2002;121:1486.

  52. Busk MF, Rosenow EC 3rd, Wilson WR. Invasive procedures in the diagnosis of pneumonia. Semin Respir Infect 1988;3:113.

  53. Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000;31:869-874.

  54. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumoniae on the usefulness of blood cultures. Respir Med 2001;95:78.

  55. Chambers DC, Waterer GW. Are blood cultures necessary in community-acquired pneumonia? Clin Pulmon Med 2005;12:146-152.

  56. Corbo J, Friedman B, Bijur P, et al. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004;221:446-448.

  57. Mandell LA, Wunderink RG, Anzuelo A, et al. Infectious Diseases Society of Ameria/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. CID 2007;44(Suppl 2):S27-S72.

  58. Yu VL, Plouffe JF, Pastris MC, et al. Distribution of Legionella species and serogrups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002;186:127.

  59. Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005;41:345.

  60. Prat C, Lacoma A, Dominguez J, et al. Midregional pro-atrial antriuretic peptide as a prognostic marker in pneumoniae. J Infect 2007;55:400-407.

  61. Salluh JI, Bozza FA, Soares M, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest 2008;134:947-954.

  62. Masiá M, Papassotiriou J, Morgenthaler NG, et al. Midregional pro-A-type natriuretic peptide and corboxi-terminal pro-vasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007;53:2193-2201.

  63. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-225.

  64. Hiraka Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diaagn Microbiol Infect Dis 2008;61:170-1748.

  65. Huang DT, Weissfeld LA, Kellum JA, et al. GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in commmunity-acquired pneumonia. Ann Emerg Med 2008;52:48-58.

  66. Christ-Crain MSD, Stolz D, Bingisser R, et al. Procalcitonin: guidance of antibiotic therapy in community-acquired pneumonia in an Intensive Care Unit. Infection 2005;33:257-263.

  67. Torres A, Rello J. Update in community-acquired and nosocomial pneumonia 2009. Am J Respir Crit Care Med 2010;181:782-787.

  68. Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la neumonía adquirida en la comunidad. Arch Bronconeumol 2004;40:364-374.

  69. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382.

  70. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumoniae. N Engl J Med 1997;336:243-250.

  71. Charles PG, Wolfe R, Whitby M, et al, Australian Community-Acquired Pneumonia Study Collaboration, Grayson ML. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-384.

  72. Ewig S, Ruiz M, Mensa J, et al. Sever community-acquired pneumonia. Assessment of severity criteria. Am J Respsir Crit Care Med 1998;158:1102-1108.

  73. Neumonía adquirida en la comunidad. Nueva Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 2010;46:543-558.

  74. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumoniae. JAMA 2000;283:749-755.

  75. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk clases, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33:158-165.

  76. Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states: 1993, 1995, and 1997. Chest 2001;119:1420-1426.

  77. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-1457.

  78. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002;162:1278-1284.

  79. Munafo R, Rigotti N, Lancaster T, et al. Interventions for smoking cessation in hospitalised patients: a systematic review. Thorax 2001;56:656-663.

  80. Grol R. Improving the quality of medical care. JAMA 2001;284:2578-2585.

  81. Bratzler DW, Houck PM, Jiang H, et al. Failure to vaccinate Medicare inpatients: a missed opportunity. Arch Intern Med 2002; 162:2349-56.

  82. CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) – Unites States, 2012-13 influenza season. MMWR 2012;61:613.

  83. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-1564.

  84. Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011;165:104-111.

  85. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784.

  86. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccination in the community-dwelling elderly. N Engl J Med 2007;357:1373-1381.

  87. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010;303:943-950.

  88. Moberley SA, Holdrn J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;(1):CD000422.

  89. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;(4):CD004977.

  90. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease- United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:893-897.

  91. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66:378-83.

  92. Postma DF, van Werkhoven CH, Huijts SM, Bolkenbaas M, Oosterheert JJ, Bonten MJM. New trends in the prevention and management of community-acquired pneumonia. Neth J Med 2012;70:337-348.


2013, Suplemento 1

2013; 72 (S1)